A Phase 1 Study to Evaluate the Absorption, Metabolism, and Disposition of Dordaviprone in Healthy Adult Participants

Documenti analoghi

• Utility of Cytochrome P450 4F2 Genotyping to Assess Drug Interaction Risk for Brincidovovir, a Cytochrome P450 4F2 Substrate
  di: Tim Tippin, et al.
  Pubblicazione: (2024)
• Relative Bioavailability of Dordaviprone (ONC201) is Not Affected by Co‐Administration of the Proton‐Pump Inhibitor Rabeprazole
  di: Shamia L. Faison, et al.
  Pubblicazione: (2024)
• A phase 1, randomized, crossover trial to assess the effect of itraconazole on the pharmacokinetics of dordaviprone in healthy adults
  di: Shamia L. Faison, et al.
  Pubblicazione: (2025)
• Assessing Cytochrome P450 Drug Interaction Risk for Dordaviprone Using Physiologically Based Pharmacokinetic Modeling
  di: Swati Jaiswal, et al.
  Pubblicazione: (2025)
• Disposition and Absolute Bioavailability of Orally Administered Orforglipron in Healthy Participants
  di: Bridget L. Morse, et al.
  Pubblicazione: (2025)